Takeda Reports Positive Data From Phase 4 Entyvio Trial
Takeda said the VERDICT trial evaluated Entyvio in ulcerative colitis and related complications.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Takeda Reports Phase 4 VERDICT Data on ENTYVIO in Ulcerative Colitis
Takeda said Phase 4 VERDICT data showed ENTYVIO treat-to-target disease clearance prolonged time to a first ulcerative colitis-related complication versus symptomatic remission alone (HR 0.33; 95% CI 0.17–0.67; P=0.0014). Safety was consistent with prior data.